These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 25585651)

  • 1. Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches.
    Pinder SE; Rakha EA; Purdie CA; Bartlett JM; Francis A; Stein RC; Thompson AM; Shaaban AM;
    Histopathology; 2015 Sep; 67(3):279-93. PubMed ID: 25585651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
    Patel T; Gupta A; Shah M
    J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant treatment of breast cancer: implications for the pathologist].
    Le Guellec S; Perallon R; Alunni JP; Charitansky H; Leaha C; Gonzalez AM; Chateau MC; Simony-Lafontaine J; Jacot W; Gutowski M; Penault-Llorca F; Dalenc F; Lacroix-Triki M
    Ann Pathol; 2011 Dec; 31(6):442-54. PubMed ID: 22172117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer.
    Tewari M; Pradhan S; Singh U; Singh TB; Shukla HS
    Asian J Surg; 2010 Oct; 33(4):157-67. PubMed ID: 21377101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
    Viale G
    Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
    Cockburn A; Yan J; Rahardja D; Euhus D; Peng Y; Fang Y; Rumnong Sarode V
    Hum Pathol; 2014 Feb; 45(2):249-58. PubMed ID: 24289969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens.
    Provenzano E; Brown JP; Pinder SE
    Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):80-92. PubMed ID: 23199579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer.
    Qin Q; Gao F; Jiang W; Tan Q; Mo Q; Wei C
    Chin Med J (Engl); 2014; 127(18):3272-7. PubMed ID: 25266526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
    Yang YF; Liao YY; Li LQ; Xie SR; Xie YF; Peng NF
    Pathol Res Pract; 2013 Dec; 209(12):797-802. PubMed ID: 24183366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker assessment and molecular testing for prognostication in breast cancer.
    Kos Z; Dabbs DJ
    Histopathology; 2016 Jan; 68(1):70-85. PubMed ID: 26768030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients].
    Zhou YJ; Ying M; He YJ; Liu YQ; Fan ZQ; Fan T; Li JF; Wang TF; Xie YT; Lu AP; Ouyang T
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1711-5. PubMed ID: 24124677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
    Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
    BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.